Buprenorphine Transdermal System Patch, Extended Release
NDC Package 47781-408-04
Package Information
Buprenorphine Transdermal System (buprenorphine) patches is buprenorphine transdermal system is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. This formulation utilizes a patch, extended release delivery system. Marketed by Alvogen Inc., this product is identified by NDC 47781-408 and is authorized under FDA application ANDA207490.
Identification & Billing
- RxCUI: 1432969 - buprenorphine 15 MCG/HR 7 Day Transdermal System
- RxCUI: 1432969 - 168 HR buprenorphine 0.015 MG/HR Transdermal System
- RxCUI: 1432969 - buprenorphine 15 MCG/HR Weekly Transdermal Patch
- RxCUI: 904870 - buprenorphine 10 MCG/HR 7 Day Transdermal System
- RxCUI: 904870 - 168 HR buprenorphine 0.01 MG/HR Transdermal System
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 47781 - Alvogen Inc.
- 47781-408 - Buprenorphine Transdermal System
- 47781-408-04 - 4 POUCH in 1 CARTON / 1 PATCH in 1 POUCH (47781-408-11) / 168 h in 1 PATCH
- 47781-408 - Buprenorphine Transdermal System
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 47781-408-04 identifies a specific commercial package of 4 pouch in 1 carton / 1 patch in 1 pouch (47781-408-11) / 168 h in 1 patch of Buprenorphine Transdermal System, a human prescription drug labeled by Alvogen Inc.. This patch, extended release is formulated for transdermal use and contains buprenorphine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alvogen Inc. on May 17, 2022.
How is this Alvogen Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 47781040804. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.